A randomised, double-blind, double-dummy, cross-over multicenter study to demonstrate equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60/30 mg PR, OXN80/40 mg PR) twice daily compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy.

Mundipharma Research GmbH & Co. KG0 个研究点目标入组 200 人2014年10月3日

适应症The intended indication is:Chronic severe non malignant pain, chronic severe malignant pain, requiring opioids.MedDRA version: 17.0Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditions Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]

相关药物Targinact 10/5mg Targinact 20/10mg

概览

阶段: 1 期
干预措施: 未指定
疾病 / 适应症: The intended indication is:Chronic severe non malignant pain, chronic severe malignant pain, requiring opioids.
发起方: Mundipharma Research GmbH & Co. KG
入组人数: 200
状态: 进行中（未招募）
最后更新: 9年前

概览研究者入排标准结局指标相似试验

概览

简要总结

暂无简介。

注册库

who.int

开始日期

2014年10月3日

结束日期

待定

最后更新

9年前

研究类型

Interventional clinical trial of medicinal product

性别

All

研究者

发起方

Mundipharma Research GmbH & Co. KG

入排标准

入选标准

•Subjects to be included in the study are those who meet all of the following criteria:
•1\. Male or female subjects at least 18 years (females less than one year post\-menopausal must have a negative serum or urine pregnancy test prior to the first dose of study treatment, be non\-lactating, and willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasoectomised partner).
•2\. Subjects receiving WHO step III opioid analgesic medication for the treatment of severe non\-malignant or malignant pain in the oxycodone equivalent range of 100 ? 160 mg per day, who could benefit from improved analgesic efficacy, improved tolerability or optimised treatment regimen (e.g. reduction of number of different drugs, less different formulation usage/route of applications).
•3\. Documented history of severe non\-malignant or malignant pain that will require around\-the\-clock opioid therapy for a minimum of 6 weeks (OXN60/30 mg PR or OXN80/40 mg PR twice daily).
•4\. Subjects must be willing to change/adapt their current opioid analgesic treatment/regimen.
•5\. Subjects must be willing and able (e.g. mental and physical condition) to participate in all aspects of the study, including use of medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, and compliance with protocol requirements as evidenced by providing written, informed consent.
•6\. In the Investigator?s opinion the subject?s non\-analgesic concomitant medications, including those medications for the treatment of depression are thought to be stable, and will remain stable throughout the Double\-blind Phase of the study.
•7\. In the Investigator?s opinion the non\-opioid analgesic medication dose will remain stable during the Double\-blind Phase.
•Are the trial subjects under 18? no
•Number of subjects for this age range:

排除标准

•Subjects to be excluded from the study are those who meet any of the following criteria:
•1\. Any history of hypersensitivity to oxycodone, naloxone, related products or other ingredients of the study treatment.
•2\. Any contraindication to oxycodone, naloxone and other ingredients of the study treatment.
•3\. Subjects with any situation in which opioids are contraindicated (e.g. severe respiratory depression with hypoxia and/or hypercapnia, severe chronic obstructive lung disease, paralytic ileus).
•4\. Subjects already receiving OXN PR plus additional opioid and being dissatisfied due to unacceptable tolerability of OXN PR.
•5\. Active alcohol or drug abuse and/or history of opioid abuse.
•6\. Subjects with a positive urine drug test at screening visit 1, which indicates unreported illicit drug use or unreported use of a concomitant medication not required to treat the subjects? medical condition(s).
•7\. Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal (e.g. paralytic ileus), or psychiatric disease, as determined by medical history, clinical laboratory tests, ECG results, and physical examination, that would place the subject at risk upon exposure to the study treatment or that may confound the analysis and/or interpretation of the study results.
•8\. Chronic or intermittent pain that results from Fibromyalgia or Rheumatoid Arthritis.
•9\. Subjects with hypothyroidism (non\-compensated), Addison\`s disease or increase of intracranial pressure.